BNP (Brain Natriuretic Peptide) / Nesiritide
Also known as: Brain Natriuretic Peptide, Nesiritide, Natrecor, B-type NP
Overview
Brain Natriuretic Peptide (BNP) is a 32-amino acid cardiac-derived natriuretic peptide produced primarily by ventricular cardiomyocytes in response to increased myocardial wall stress and volume overload. It acts through natriuretic peptide receptors (NPR-A) to reduce cardiac preload and afterload, making it both a diagnostic biomarker (NT-proBNP) and a therapeutic target. Nesiritide (Natrecor), a recombinant BNP, was FDA-approved in 2001 for acutely decompensated heart failure, providing rapid preload and afterload reduction through natriuresis, vasodilation, and sympatholysis.
Mechanism of Action
BNP/nesiritide binds natriuretic peptide receptor A (NPR-A/guanylyl cyclase A), activating cGMP production. Elevated cGMP activates PKG (protein kinase G), which relaxes vascular smooth muscle (vasodilation), inhibits aldosterone secretion, reduces sympathetic nervous system tone, promotes renal natriuresis/diuresis, and suppresses cardiac fibrosis and hypertrophy. Preload reduction occurs via venodilation, afterload reduction via arteriodilation, and renal effects via enhanced natriuresis/GFR improvement.
Potential Benefits
- Acute preload and afterload reduction in decompensated heart failure
- Natriuresis and diuresis without direct tubular toxicity
- Sympatholytic activity reducing neurohormonal activation
- Diagnostic biomarker (NT-proBNP) for heart failure severity
- Anti-fibrotic and anti-hypertrophic in chronic cardiac remodeling
Dosage Protocols
The following reflects doses used in published research studies. This is not medical advice. Consult a qualified healthcare professional.
| Beginner | Hospital use only — ICU/CCU administration |
| Intermediate | N/A |
| Advanced | N/A |
| Cycle Duration | Up to 48 hours (acute decompensated HF) |
FDA-approved (Natrecor) for acute decompensated heart failure. Use declined after ASCEND-HF trial showed no mortality benefit.
Use our Reconstitution Calculator to determine exact syringe units for your protocol.
Routes of Administration
Intravenous 100%
Hospital IV infusion only. Requires BP and renal monitoring.
Read our full Routes of Administration Guide for detailed comparison of all delivery methods.
Stacking Protocols
Popular research stacks involving BNP (Brain Natriuretic Peptide) / Nesiritide:
Acute HF Management
Hospital-based acute decompensated HF protocol — nesiritide + furosemide infusion.
Explore our complete Peptide Stacking Guide for more combinations and safety considerations.
Reconstitution
| Storage | Refrigerate 2-8°C. After reconstitution, use within 24 hours. |
|---|
Hospital pharmacy preparation. Do not add other drugs to the infusion line.
Need exact syringe measurements?
Amino Acid Sequence
Ser-Pro-Lys-Met-Val-Gln-Gly-Ser-Gly-Cys-Phe-Gly-Arg-Lys-Met-Asp-Arg-Ile-Ser-Ser-Ser-Ser-Gly-Leu-Gly-Cys-Lys-Val-Leu-Arg-Arg-His (cyclic via disulfide Cys10-Cys26)
Side Effects & Safety
- Hypotension (most common, dose-limiting)
- Headache
- Nausea
- Potential worsening of renal function at high doses
Safety & Contraindications
This information is for educational purposes only. Consult a qualified healthcare provider before using any peptide.
Pregnancy / Lactation
Bleeding Disorders
Active Skin Infection at Injection Site
Pharmacokinetics
| Half-Life | ~18 minutes |
|---|---|
| Storage | Refrigerate at 2-8°C. Protect from light. |
Synergistic Compounds
The following compounds have been studied alongside BNP (Brain Natriuretic Peptide) / Nesiritide for potential complementary or synergistic effects:
Learn More
References & Further Reading
Latest News & Research
View all articles →
FDA Staff Reviewers Say ‘No’ to 7 Compounded Peptides Ahead of July PCAC Vote
FDA staff reviewers urged against adding seven popular peptides to the 503A bulks list ahead of the July PCAC meeting, citing weak human data and safety uncertainty.
FDA reviewers urge ‘no’ on BPC-157, TB-500, MOTS-c ahead of July 2026 compounding vote
FDA reviewers’ June 29 briefings recommend against listing seven popular peptides for 503A compounding, citing limited human data and immunogenicity risk.
Medicare Starts Paying for Obesity Drugs Today — Bridge Program Opens $50 Access for Millions
Medicare's new $50 Bridge program covering Wegovy, Zepbound, Foundayo, and oral Wegovy for obesity launched July 1 — the first Medicare weight-loss benefit.
FDA staff urges caution on compounded peptides ahead of July advisory meeting
Ahead of the July 23–24 Pharmacy Compounding Advisory Committee meeting, FDA staff briefings recommend against listing seven popular peptides for compounding.